Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinical Laserthermia Systems AB has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Clinical Laserthermia Systems AB did not have earnings to cover the interest expense.
Clinical Laserthermia Systems AB's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.00.
As of today, Clinical Laserthermia Systems AB's Altman Z-Score is -0.79.
Clinical Laserthermia Systems AB (FRA:LS60) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Clinical Laserthermia Systems AB has the Financial Strength Rank of 7.
Clinical Laserthermia Systems AB Financial Strength Related Terms
FRA:LS60 vs ABT, SYK, MDT: Financial Strength Comparison
For the Medical Devices subindustry, Clinical Laserthermia Systems AB's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinical Laserthermia Systems AB Financial Strength vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Clinical Laserthermia Systems AB's Financial Strength distribution charts can be found below:
* The bar in red indicates where Clinical Laserthermia Systems AB's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Clinical Laserthermia Systems AB has a Z-score of -0.79, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -0.79 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinical Laserthermia Systems AB (FRA:LS60) has a Financial Strength of 7 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Clinical Laserthermia Systems AB and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Clinical Laserthermia Systems AB's Financial Strength has ranged from 1.00 to 9.00.
Is Clinical Laserthermia Systems AB's Financial Strength too high?
Clinical Laserthermia Systems AB's current Financial Strength of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's Financial Strength compare to ABT and SYK?
Clinical Laserthermia Systems AB's Financial Strength of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Clinical Laserthermia Systems AB's own Financial Strength has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Medical Devices & Instruments company?
A good Financial Strength depends on the Medical Devices & Instruments industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Clinical Laserthermia Systems AB and its competitors. Clinical Laserthermia Systems AB's current Financial Strength is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (FRA:LS60) is currently considered Possible Value Trap. The stock's GF Value™ is €0.21, compared to a current price of €0.12 — trading 42.4% below its estimated fair value. The current Financial Strength is 7, which is 40% above median its 10-year median of 5.00. Clinical Laserthermia Systems AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (FRA:LS60), the current Financial Strength is 7 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinical Laserthermia Systems AB (FRA:LS60) Overvalued in 2026?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued.
The current stock price of €0.12 is trading 42.4% below its estimated GF Value™ of €0.21.
GuruFocus considers Clinical Laserthermia Systems AB to be Possible Value Trap.
Key valuation signals for FRA:LS60:
Financial Strength: 7 (40% above median its 10-year median of 5.00)
GF Value™: €0.21 vs. price of €0.12 (42.4% below fair value)
No single metric tells the full story. See the FRA:LS60 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
41GF Score
Get the complete analysis for FRA:LS60
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LS60 has been successfully added to your 
